

Drugs and Therapeutics (D & T) Committee

Meeting Results

April 6, 2023

Drug Name	Review Type	Committee Recommendation	Preferred Status – Final Determination
Briumvi	New Drug Initial Review	Non-Preferred	Non-Preferred
Sunlenca	New Drug Initial Review	Preferred with PA	Preferred with PA
Tzield	New Drug Appeal	Non-Preferred	Non-Preferred
Perseris	New Drug Appeal	Preferred with PA	Non-Preferred

Oral Atypical Antipsychotics Class Review			
Drug Name	PDL Status		
Abilify			Non-preferred
Aripiprazole ODT			Non-preferred
Aripiprazole tablets	Preferred		
Asenapine			Non-preferred
Caplyta*			Non-preferred
Chlordiazepoxide/Amitriptyline	Preferred		
Chlorpromazine Concentrate	Preferred		
Chlorpromazine tablets	Preferred		
Clozapine	Preferred		

Clozapine ODT			Non-preferred
Clozaril			Non-preferred
Compro suppositories	Preferred		
Equetro			Non-preferred
Fanapt			Non-preferred
Fluphenazine tablets	Preferred		
Fluphenazine Concentrate	Preferred		
Fluphenazine Elixir	Preferred		
Geodon			Non-preferred
Haloperidol Concentrate	Preferred		
Haloperidol tablets	Preferred		
Invega			Non-preferred
Latuda			Non-preferred
Lithium capsules	Preferred		
Lithium tablets	Preferred		
Lithium ER tablets	Preferred		
Loxapine	Preferred		
Lurasidone	Preferred		
Lybalvi			Non-preferred
Nuplazid			Non-preferred
Olanzapine/Fluoxetine			Non-preferred
Olanzapine	Preferred		
Olanzapine ODT	Preferred		
Paliperidone ER			Non-preferred
Perphenazine/Amitriptyline	Preferred		
Perphenazine	Preferred		
Prochlorperazine	Preferred		
Prochlorperazine suppositories	Preferred		

Quetiapine	Preferred		
Quetiapine ER	Preferred		
Rexulti*			Non-preferred
Risperidone tablets	Preferred		
Risperidone solution	Preferred		
Risperidone ODT			Non-preferred
Saphris sublingual			Non-preferred
Secuado Patch			Non-preferred
Seroquel			Non-preferred
Seroquel XR			Non-preferred
Symbax			Non-preferred
Thioridazine	Preferred		
Thiothixene	Preferred		
Trifluoperazine	Preferred		
Vraylar*			Non-preferred
Ziprasidone	Preferred		
Zyprexa			Non-preferred
Zyprexa ODT			Non-preferred

Please Note: Drug Status changes are noted in [Blue](#). For the drugs denoted with *(Vraylar, Caplyta, Rexulti), the Illinois Drugs and Therapeutics Board recommended the products be moved preferred with PA status. The Board recommendation was based on a concern that currently preferred products do not offer enough protection for those patients that experience a metabolic issue (weight gain). After much clinical review, the Department found that both aripiprazole and lurasidone offer similar therapeutic efficacy and metabolic protection as the denoted products.

CGRP Anti-migraine Class Review			
Drug Name	PDL Status		
Emagality		Preferred with PA	
Qulipta		Preferred with PA	

Ajovy		Preferred with PA	
Aimovig		Preferred with PA	
Vyepti			Non-preferred
Nurtec		Preferred with PA	
Ubrelvy		Preferred with PA	
Reyvow			Non-preferred

Please Note: Drug Status changes are noted in [Blue](#).

Other Board Recommendations

Oral Albuterol Syrup review

Albuterol syrup has been removed from the national guidelines because it has been proven to be less effective and have more side effects than inhaled versions of Albuterol. The Board recommended that oral Albuterol syrup be moved from preferred to non-preferred on the PDL and reserved for use only when inhaled versions are inappropriate based on diagnosis. The Department has accepted this recommendation and Albuterol Syrup will become non-preferred.

Hepatitis C

The D&T Advisory Board considered the current PDL status of Hepatitis C drugs, Mavyret and generic Epclusa which are preferred with PA. Coverage offered by these 2 drugs, risks and benefits were discussed. The D&T Board then voted unanimously to make these 2 preferred drugs available without the PA upon prescription by those non-specialist practitioners who have completed a one hour continuing medical education course (CME) focused on diagnosis, appropriate management, and recommended follow up of patients with Hepatitis C, given by accredited organizations. The Department has accepted that recommendation to go into effect July 1, 2023.

The minutes reflecting these D&T Advisory Board actions are contained in draft minutes, yet to be approved at the next board meeting. Following that, this post will be updated only if there are amendments to those minutes.